1. Home
  2. EQ vs CSTE Comparison

EQ vs CSTE Comparison

Compare EQ & CSTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EQ
  • CSTE
  • Stock Information
  • Founded
  • EQ 2017
  • CSTE 1987
  • Country
  • EQ United States
  • CSTE Israel
  • Employees
  • EQ N/A
  • CSTE N/A
  • Industry
  • EQ Biotechnology: Pharmaceutical Preparations
  • CSTE Building Materials
  • Sector
  • EQ Health Care
  • CSTE Industrials
  • Exchange
  • EQ Nasdaq
  • CSTE Nasdaq
  • Market Cap
  • EQ 67.9M
  • CSTE 61.9M
  • IPO Year
  • EQ 2018
  • CSTE 2012
  • Fundamental
  • Price
  • EQ $1.88
  • CSTE $1.39
  • Analyst Decision
  • EQ Hold
  • CSTE
  • Analyst Count
  • EQ 2
  • CSTE 0
  • Target Price
  • EQ $1.00
  • CSTE N/A
  • AVG Volume (30 Days)
  • EQ 16.1M
  • CSTE 55.8K
  • Earning Date
  • EQ 08-14-2025
  • CSTE 08-06-2025
  • Dividend Yield
  • EQ N/A
  • CSTE N/A
  • EPS Growth
  • EQ N/A
  • CSTE N/A
  • EPS
  • EQ N/A
  • CSTE N/A
  • Revenue
  • EQ $16,553,000.00
  • CSTE $406,178,000.00
  • Revenue This Year
  • EQ N/A
  • CSTE N/A
  • Revenue Next Year
  • EQ N/A
  • CSTE $5.61
  • P/E Ratio
  • EQ N/A
  • CSTE N/A
  • Revenue Growth
  • EQ N/A
  • CSTE N/A
  • 52 Week Low
  • EQ $0.27
  • CSTE $1.35
  • 52 Week High
  • EQ $2.35
  • CSTE $5.04
  • Technical
  • Relative Strength Index (RSI)
  • EQ 68.96
  • CSTE 34.55
  • Support Level
  • EQ $1.50
  • CSTE $1.35
  • Resistance Level
  • EQ $2.35
  • CSTE $1.47
  • Average True Range (ATR)
  • EQ 0.35
  • CSTE 0.08
  • MACD
  • EQ -0.00
  • CSTE 0.00
  • Stochastic Oscillator
  • EQ 62.10
  • CSTE 17.39

About EQ Equillium Inc.

Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.

About CSTE Caesarstone Ltd.

Caesarstone Ltd manufactures engineered quartz surfaces. Its products include engineered quartz and porcelain slabs, which are used as kitchen countertops in renovation and remodeling, and residential construction. It also has other applications, including vanity tops, wall panels, backsplashes, floor tiles, stairs, and other interior surfaces that are used in various residential and non-residential applications. The company sells its products under the Caesarstone brand. Caesarstone's geographical segments are the United States, Canada, Latin America, Australia, Asia, Israel, and EMEA(Europe, Middle East, Africa).

Share on Social Networks: